Learning Center

Presentation Abstract

 

British Society for Immunology
December 6-10, 2010
Liverpool, UK

 

A randomised controlled trial to assess the ability of yeast-derived 1,3/1,6 glucopolysaccharide to reduce upper respiratory tract infection symptoms

 

R. Fuller1, T. Yam2, H. Butt3, P. Calder3, J. Kenyon1, P. Noakes3

 

1The Dove Clinic, Twyford, Winchester, 2Southampton University Hospitals NHS Trust, Southampton General Hospital, 3School of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK

 

Wellmune WGP is a food supplement containing 1,3/1,6 glucopolysaccharide derived from the cell wall of yeast (Saccharomyces cerevisiae). Previous studies demonstrated improved chemotaxis and phagocytosis in human innate immune cells via priming of Complement Receptor-3. Increased survival in animals challenged with pathogens in vivo and significant reduction in Upper Respiratory Tract Infection (URTI) symptom frequency have been reported previously. This study was a randomised double-blind placebo-controlled trial over 90 days during peak URTI season. 100 individuals were recruited and randomised to receive Wellmune WGP 250mg once daily (n=50) or an identical placebo capsule (n=50), mean ages 21.94 vs 21.28 respectively. Routine blood tests, serum cytokine and chemokine samples were measured at Day 0 and Day 90. Participants completed a daily health diary. Two or more URTI symptoms for 2 consecutive days triggered assessment and cytokine analysis within 24-hours. Symptom severity was monitored using a validated score (WURSS-21). The number of days with reported URTI symptoms was significantly reduced in the Wellmune WGP group compared to placebo (198 v's 241, p=0.039). There was a trend (p>0.05) towards reduced symptom severity in the active group. Side-effect profiles were similar in active and placebo groups with transient symptoms only. Cytokine data showed no significant difference between active and placebo groups, suggesting that daily administration of Wellmune WGP 250mg does not induce inflammatory cytokine changes either at rest or during immune challenge such as URTI. Further investigation of the potential role of Wellmune WGP to increase host resistance via innate immune response is warranted

 

.

Immune Health Basics products contain Wellmune WGP®


How does it work? Watch Video
training_date